
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
CROSSJECT SA EO -,10 74C FR0011716265
AB/FROM ONWARDS 08.04.2024 15:07 CET
© 2024 Xetra Newsboard
Realtime | Geld | Brief | Zeit |
---|---|---|---|
1,088 | 1,120 | 08:36 |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
27.03. | CROSSJECT reports financial results for 2024 | Press Release CROSSJECT reports financial results for 2024 Continued satisfactory production of regulatory batches with a view to filing in Q2 2025.Recruitment of Tony Tipton as Chief Operating Officer... ► Artikel lesen | |
25.03. | CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO adrenal insufficiency program | Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals,... ► Artikel lesen | |
18.03. | CROSSJECT achieves key ZEPIZURE manufacturing batch stability milestones | ||
12.02. | Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board | Dijon, FRANCE, February 12, 2025 - 0730 (CET) - Crossject (ISIN: FR0011716265; Euronext Growth: ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free... ► Artikel lesen | |
19.12.24 | Crossject confirms ZEPIZURE supply chain readiness with another successful ISO audit for Quality Management System | Crossject successfully passes another ISO 13485 audit for sites in Dijon and Gray (France)Company is ramping up supply chain to prepare for commercialization in U.S. Dijon, France, December 19, 2024... ► Artikel lesen |